Centre Asset Management Boosted Quanta Services (PWR) Stake By $361,860; Integra Lifesciences Holdings (IART) Sentiment Is 0.98

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $4.22 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 87.89 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

Centre Asset Management Llc increased Quanta Services Inc (PWR) stake by 4.26% reported in 2017Q3 SEC filing. Centre Asset Management Llc acquired 9,780 shares as Quanta Services Inc (PWR)’s stock declined 15.57%. The Centre Asset Management Llc holds 239,130 shares with $8.94 million value, up from 229,350 last quarter. Quanta Services Inc now has $5.42B valuation. It closed at $35.17 lastly. It is up 39.30% since March 9, 2017 and is uptrending. It has outperformed by 22.60% the S&P500.

Among 15 analysts covering Quanta Services Inc. (NYSE:PWR), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Quanta Services Inc. has $53 highest and $20 lowest target. $41.42’s average target is 17.77% above currents $35.17 stock price. Quanta Services Inc. had 51 analyst reports since August 6, 2015 according to SRatingsIntel. As per Friday, May 6, the company rating was maintained by FBR Capital. The stock of Quanta Services, Inc. (NYSE:PWR) has “Buy” rating given on Friday, July 7 by Stifel Nicolaus. The stock of Quanta Services, Inc. (NYSE:PWR) earned “Accumulate” rating by Johnson Rice on Monday, October 19. The rating was upgraded by UBS to “Buy” on Thursday, July 13. The rating was upgraded by Citigroup on Friday, August 18 to “Buy”. The firm earned “Buy” rating on Friday, August 4 by Stifel Nicolaus. The rating was downgraded by Robert W. Baird to “Neutral” on Thursday, November 12. The rating was maintained by KeyBanc Capital Markets on Monday, November 27 with “Buy”. The stock has “Buy” rating by Stifel Nicolaus on Sunday, December 10. As per Friday, October 6, the company rating was maintained by Stifel Nicolaus.

The stock decreased 0.02% or $0.01 during the last trading session, reaching $53.7. About 420,845 shares traded. Integra LifeSciences Holdings Corporation (IART) has risen 32.67% since March 9, 2017 and is uptrending. It has outperformed by 15.97% the S&P500.

Sector Gamma As holds 4.07% of its portfolio in Integra LifeSciences Holdings Corporation for 529,230 shares. Champlain Investment Partners Llc owns 4.54 million shares or 2.7% of their US portfolio. Moreover, Falcon Point Capital Llc has 1.73% invested in the company for 255,207 shares. The Colorado-based Tributary Capital Management Llc has invested 1.61% in the stock. Pier Capital Llc, a Connecticut-based fund reported 112,576 shares.